Early HTA

Early Stage Health Technology Assessment

Early Health Technology Assessment, including early Health Economic Modeling, is increasingly promoted as an approach to determine added value of potential new technologies early in the development pipeline. Such assessment would be useful to (1) decide about further development of the technology, (2) to define minimum performance thresholds for the new technology compared to currently available technologies and (3) to support pricing and reimbursement in early stages of development. It thereby considers existing regulatory requirements in several countries as well as mechanisms for obtaining reimbursement depending on the added value produced. Early HTA deviates from mainstream HTA as it primarily informs R&D instead of government (agencies) deciding about coverage.

Key publications:

  • Rogowski WH, John J, IJzerman MJ. Translational Health Economics. In: World Scientific Handbook of Global Health Economics and Public Policy. 3rd ed. World Scientific Publishing Company; 2016.
  • Middelkamp HHT, van der Meer AD, Hummel JM, Stamatialis DF, Mummery CL, Passier R, et al. Organs-on-Chips in Drug Development: The Importance of Involving Stakeholders in Early Health Technology Assessment. Applied In Vitro Toxicology. 2016 Feb 19
  • Fermont JM, Douw KHP, Vondeling H, IJzerman MJ. Ranking medical innovations according to perceived health benefit. Health Policy and Technology. 2016 Feb..
  • Markiewicz K, van Til JA, IJzerman MJ. Commercial viability of medical devices using Headroom and retunr on investment calculation. Technological Forecasting and Social Change. 2016 Aug 20.
  • de Windt TS, Sorel JC, Vonk LA, Kip MMA, IJzerman MJ, Saris DBF. Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine. J Tissue Eng Regen Med. 2016 Jul 12.
  • Markiewicz K, van Til JA, IJzerman MJ. Medical devices early assessment methods: systematic literature review. Int J Technol Assess Health Care. 2014 May 7;:1–10.
  • IJzerman MJ, Steuten LMG. Early Assessment of Medical Technologies to Inform Product Development and Market Access. Appl Health Econ Health Policy. 2011 Sep;9(5):331–47.
  • Van de Wetering G, Steuten LMG, Birgelen von C, Adang EMM, IJzerman MJ. Early Bayesian modeling of a potassium lab-on-a-chip for monitoring of heart failure patients at increased risk of hyperkalaemia. Technological Forecasting and Social Change. 2012 Sep;79(7):1268–79.